XML 56 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies (Narrative) (Details)
 12 Months Ended
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Dec. 31, 2019
GBP (£)
segment
Dec. 31, 2019
USD ($)
segment
Accounting Policies [Line Items]        
Right-of-use lease asset       $ 1,264,000
Cash and cash equivalents   $ 17,504,000   11,885,000
Cash exceeding balance insured by FDIC       11,100,000
Cash balance insured by FSCS | £     £ 85,000  
Cash exceeding balance insured by FSCS       $ 500,000
Number of operating segments | segment 1      
Number of geographic areas for development operations | segment     2 2
Tax on other comprehensive income (loss) $ 0 0    
Reclassifications out of other comprehensive income (loss) $ 0 0    
Lease, practical expedients package true      
ManRos Therapeutics SA ("ManRos") [Member] | Collaboration, Supply and Licensing Agreements [Member]        
Accounting Policies [Line Items]        
Payment received from achieving a clinical milestone $ 0      
Maximum [Member]        
Accounting Policies [Line Items]        
Cash balances insured by FDIC       $ 250,000
ASU 2016-02 [Member]        
Accounting Policies [Line Items]        
Operating lease liability       1,500,000
Right-of-use lease asset       $ 1,500,000
Property, plant and equipment | Minimum [Member]        
Accounting Policies [Line Items]        
Estimated useful life 3 years      
Property, plant and equipment | Maximum [Member]        
Accounting Policies [Line Items]        
Estimated useful life 5 years      
Leasehold Improvements [Member] | Minimum [Member]        
Accounting Policies [Line Items]        
Estimated useful life 5 years      
Leasehold Improvements [Member] | Maximum [Member]        
Accounting Policies [Line Items]        
Estimated useful life 15 years      
Collaboration and research and development revenue [Member] | ManRos Therapeutics SA ("ManRos") [Member] | Collaboration, Supply and Licensing Agreements [Member]        
Accounting Policies [Line Items]        
Payment received from achieving a clinical milestone   $ 150,000